578 related articles for article (PubMed ID: 28822451)
1. [The value of serum free light chain in differential diagnosis of monoclonal gammopathy of renal significance].
Li C; Wen YB; Li H; Su W; Li J; Cai JF; Chen LM; Li XM; Li XW
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(30):2344-2348. PubMed ID: 28822451
[No Abstract] [Full Text] [Related]
2. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
3. Kidney Histopathologic Spectrum and Clinical Indicators Associated with MGRS.
Yong ZH; Yu XJ; Liu JX; Zhou FD; Wang SX; Zhao MH
Clin J Am Soc Nephrol; 2022 Apr; 17(4):527-534. PubMed ID: 35210280
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performances of M-protein tests according to the clinical presentations of kidney disease.
Koo EH; Shin JH; Jang HR; Park HD; Kwon GY; Huh W; Kim DJ; Kim YG; Oh HY; Lee JE
Eur J Intern Med; 2016 Sep; 33():88-92. PubMed ID: 27421913
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of monoclonal gammopathy of renal significance.
Bridoux F; Leung N; Hutchison CA; Touchard G; Sethi S; Fermand JP; Picken MM; Herrera GA; Kastritis E; Merlini G; Roussel M; Fervenza FC; Dispenzieri A; Kyle RA; Nasr SH;
Kidney Int; 2015 Apr; 87(4):698-711. PubMed ID: 25607108
[TBL] [Abstract][Full Text] [Related]
7. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
[TBL] [Abstract][Full Text] [Related]
8. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
[TBL] [Abstract][Full Text] [Related]
10. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of patients with paraproteinemia and renal damage.
Tang X; Wan F; Yu J; Li X; Yang R; Zhu B
Eur J Med Res; 2021 Jul; 26(1):68. PubMed ID: 34217367
[TBL] [Abstract][Full Text] [Related]
12. Serum free light chains in clinical laboratory diagnostics.
Jenner E
Clin Chim Acta; 2014 Jan; 427():15-20. PubMed ID: 23999048
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Significance of Serum Free Light Chain in Monoclonal Gammopathy].
Lu H; Zhang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):155-158. PubMed ID: 38387914
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies.
Wood PB; McElroy YG; Stone MJ
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):278-80. PubMed ID: 20709664
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.
Steiner N; Göbel G; Suchecki P; Prokop W; Neuwirt H; Gunsilius E
Oncotarget; 2018 Jan; 9(2):2344-2356. PubMed ID: 29416776
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review.
Huang J; Sun C; Su H; Zhang C; Xiong J
Kidney Blood Press Res; 2019; 44(4):858-869. PubMed ID: 31352451
[TBL] [Abstract][Full Text] [Related]
20. Screening panels for detection of monoclonal gammopathies.
Katzmann JA; Kyle RA; Benson J; Larson DR; Snyder MR; Lust JA; Rajkumar SV; Dispenzieri A
Clin Chem; 2009 Aug; 55(8):1517-22. PubMed ID: 19520758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
